AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01050595
Drug: Methylnaltrexone Bromide
RxNorm normalized name: Methylnaltrexone Bromide
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance \<30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
Trial: NCT01050595
Drug: Placebo-Normal Saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
Trial: NCT02698501
Drug: MEDI9929
RxNorm normalized name: MEDI9929
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
Trial: NCT00723801
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 50mg PO QD
Trial: NCT00723801
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 100mg PO QD
Trial: NCT03348904
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.
Trial: NCT03348904
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epacadostat administered orally at the protocol-defined dose twice daily.
Trial: NCT03348904
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Trial: NCT03348904
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Trial: NCT03348904
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Trial: NCT03348904
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.
Trial: NCT03348904
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.
Trial: NCT00097591
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT00097591
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT03003676
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PD1 blockade
Trial: NCT03732638
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg tablet EOD
Trial: NCT00259753
Drug: Bevasiranib
RxNorm normalized name: Bevasiranib
DrugBank: Bevasiranib (DB06642)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00786916
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Trial: NCT00786916
Drug: lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
Trial: NCT00204191
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00753324
Drug: Routine three-drug antiretroviral prophylaxis
RxNorm normalized name: three-lobe sage extract
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
Trial: NCT00058890
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
Trial: NCT01332305
Drug: GEn (XP13512/GSK1838262)
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
Trial: NCT00572572
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
Trial: NCT01185847
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard treatment, up to 6 cycles
Trial: NCT01185847
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard treatment, up to 6 cycles
Trial: NCT01185847
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: standard treatment, up to 6 cycles
Trial: NCT03424746
Drug: disodium EDTA
RxNorm normalized name: Disodium EDTA
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label study of TACT-formula, EDTA-based chelation therapy + commercially available TACT oral multi vitamins, delivering 40-50 infusions over 1 year.
Trial: NCT01958918
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg intravitreal injection
Trial: NCT01958918
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg intravitreal injection
Trial: NCT00668460
Drug: Lactic acid (Dermacid)
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04327934
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist up to 16 days.
Trial: NCT00962429
Drug: lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Trial: NCT03713619
Drug: secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Secukinumab 300mg every 2 or every 4 weeks
Trial: NCT00351975
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00351975
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT01369290
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Trial: NCT01369290
Drug: bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Trial: NCT01369290
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Trial: NCT01369290
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Trial: NCT05702957
Drug: letrozole 2.5mg-7.5mg
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab letrozole 2.5 mg-7.5mg per day for 5 days started from 2nd day of menses.
Trial: NCT05702957
Drug: Clomiphene Citrate 50mg-150mg
RxNorm normalized name: clomiphene citrate 50 MG
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tab clomiphene citrate 50-150mg per day for 5 days started from 2nd day of menses.
Trial: NCT00504829
Drug: LCP-AtorFen
RxNorm normalized name: LCP-AtorFen
DrugBank: LCP-AtorFen (DB05769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
Trial: NCT00504829
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dyslipidemia and mixed dyslipidemia
Trial: NCT00504829
Drug: fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dyslipidemia and mixed dyslipidemia
Trial: NCT03959501
Drug: Dapagliflozin 10 mg
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10mg daily for 24 weeks
Trial: NCT03959501
Drug: Sitagliptin 100mg
RxNorm normalized name: Sitagliptin 100mg Oral tablet
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sitagliptin 100mg daily for 24 weeks
Trial: NCT02688634
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
Trial: NCT01220414
Drug: Naltrexone, then placebo
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of naltrexone
Trial: NCT01220414
Drug: Placebo, then Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sugar pill
Trial: NCT01711242
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01850160
Drug: GROUP B: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
Trial: NCT01490060
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
Trial: NCT01490060
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
Trial: NCT01490060
Drug: 5HT3 receptor antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
Trial: NCT01490060
Drug: Ifosfamide-based chemotherapy (AI)
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
Trial: NCT01490060
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
Trial: NCT02838121
Drug: Aclasta
RxNorm normalized name: Aclasta
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclasta once annually for 2 years
Trial: NCT01490060
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
Trial: NCT01490060
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
Trial: NCT00346034
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 150 to 600mg/day
Trial: NCT03549689
Drug: Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants randomized to the Switch Arm will take DTG 50mg/3TC 300mg FDC once daily with or without food at approximately the same time each day.
Trial: NCT03549689
Drug: Current tenofovir alafenamide (TAF)-containing ART regimen
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of current TAF-containing ART for 96 weeks.
Trial: NCT00383435
Drug: Mometasone furoate/formoterol (MF/F) combination
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Trial: NCT00383435
Drug: Mometasone furoate/formoterol (MF/F) combination
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Trial: NCT00383435
Drug: Mometasone furoate MDI (MF MDI)
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone (DB00764)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MF 400 mcg via metered dose inhaler twice daily for 52 weeks
Trial: NCT00383435
Drug: Formoterol MDI
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
Trial: NCT01751568
Drug: Raltegravir
RxNorm normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) orally twice daily.
Trial: NCT01063010
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
Trial: NCT00770848
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
Trial: NCT00770848
Drug: AMG 102
RxNorm normalized name: AMG 102
DrugBank: Rilotumumab (DB11972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
Trial: NCT00770848
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Q3W for a maximum of 12 cyles
Trial: NCT00770848
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg orally BID
Trial: NCT04474327
Drug: Montelukast Sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium (Singulair) will be given at a dose according to body weight. Four mg of the drug will be dissolved in four ml milk and the dose will be given once daily at 9 pm for 10 days.
Trial: NCT00352703
Drug: Kepivance (Palifermin)
RxNorm normalized name: Kepivance
DrugBank: Palifermin (DB00039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02566720
Drug: Amantadine
RxNorm normalized name: Amantadine
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
Trial: NCT00088218
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1-hour IV infusion 30 mg/m\^2 daily times 5 days (Days 1-5)
Trial: NCT00088218
Drug: Ara-C
RxNorm normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m\^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
Trial: NCT01112085
Drug: Ranibizumab 0.05mg
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
Trial: NCT01112085
Drug: Ranibizumab 0.5mg
RxNorm normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
Trial: NCT01846455
Drug: 2.0mg Buprenorphine/0.5mg Naloxone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
Trial: NCT01231698
Drug: esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
Trial: NCT02464969
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet or Solution
Trial: NCT01846455
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
Trial: NCT03065179
Drug: Nivolumab/Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV immunotherapy
Trial: NCT00650949
Drug: CYT997
RxNorm normalized name: CYT997
DrugBank: CYT997 (DB05147)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses (100mg/m\^2 to 150mg/m\^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.